Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GILEAD SCIENCES, INC.
11:08aBIONTECH : Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platf..
AQ
08:33aGILEAD SCIENCES : Kite and Appia Bio Announce Collaboration to Research and Deve..
BU
08/04GILEAD SCIENCES : Endows Its Foundation With More Than $200 Million to Support H..
AQ
08/03GILEAD SCIENCES : Endows Its Foundation With More Than $200 Million to Support H..
BU
07/29GILEAD SCIENCES : View Second Quarter 2021 Prepared Remarks
PU
07/29GILEAD SCIENCES : ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS (Form 8-K)
PU
07/29GILEAD SCIENCES : View Second Quarter 2021 Summary of Remarks
PU
07/29GILEAD : Q2 Earnings Snapshot
AQ
07/29GILEAD SCIENCES : View Second Quarter 2021 Earnings Release
PU
07/29GILEAD SCIENCES : View Second Quarter 2021 Earnings Slides
PU
07/29GILEAD SCIENCES : View Second Quarter 2021 Supplementary Info
PU
07/29GILEAD SCIENCES INC : Results of Operations and Financial Condition, Financial S..
AQ
07/29GILEAD SCIENCES : Announces Second Quarter 2021 Financial Results
BU
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
AQ
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
07/17GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
BU
07/17GILEAD SCIENCES : Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate Hig..
BU
07/15GILEAD SCIENCES : to Release Second Quarter 2021 Financial Results on Thursday, ..
BU
07/13GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
AQ
07/12GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
BU
07/05READY, SET, GO : Crystalize Your Thinking
AQ
07/02GILEAD SCIENCES : Response to Open Letter Regarding Access to AmBisome® (liposom..
PU
06/29GILEAD SCIENCES : Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free..
AQ
06/28GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
BU
06/28GILEAD SCIENCES : Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Fre..
BU
06/25GILEAD SCIENCES : Treatment with Hepcludex Was Shown to Achieve Significant Resp..
AQ
06/24GILEAD SCIENCES : Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve S..
BU
06/23GILEAD SCIENCES : Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell T..
BU
06/22GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease P..
AQ
06/22GILEAD SCIENCES : Veklury Associated With a Reduction in Mortality Rate in Hospi..
AQ
06/21GILEAD SCIENCES : Statement on New England Journal of Medicine Publication of Po..
AQ
06/21GILEAD SCIENCES : Veklury® (Remdesivir) Associated With a Reduction in Mortality..
BU
06/21GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease P..
BU
06/17GILEAD SCIENCES : Kite and Shoreline Biosciences Enter Into Strategic Partnershi..
BU
06/15GILEAD SCIENCES : Jounce Therapeutics Achieves First Milestone in Exclusive Lice..
AQ
06/14GILEAD SCIENCES : University of Cambridge - Longer-term Data for Kite's Yescarta..
AQ
06/12GILEAD SCIENCES : Longer-term Data for Kite's Yescarta® in Relapsed or Refractor..
BU
06/11GILEAD SCIENCES : U.S. Food and Drug Administration Approves New Formulation of ..
AQ
06/10GILEAD SCIENCES : U.S. Food and Drug Administration Approves New Formulation of ..
BU
06/07GILEAD SCIENCES : Trodelvy Demonstrates Superior Outcomes to Standard of Care in..
AQ
06/07GILEAD SCIENCES : Kite's Tecartus Demonstrates High Response Rate in Adults With..
AQ
06/04GILEAD SCIENCES : Kite's Tecartus® Demonstrates High Response Rate in Adults Wit..
BU
06/04GILEAD SCIENCES : Trodelvy® Demonstrates Superior Outcomes to Standard of Care i..
BU
05/26GILEAD SCIENCES : Satcher Health Leadership Institute At Morehouse School Of Med..
PR
05/19GILEAD SCIENCES : Kite Oncology to Present Transformative Science From Growing P..
BU
05/14GILEAD SCIENCES : to Present at Upcoming Investor Conferences
BU
05/14GILEAD SCIENCES INC : Submission of Matters to a Vote of Security Holders (form ..
AQ
05/06GILEAD SCIENCES : to Present at Upcoming Investor Conferences
BU
05/06GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
04/28GILEAD SCIENCES : Year in Review 2020
PU
04/27GILEAD SCIENCE LOSES OPPOSITION TO G : No Section 2(d) Likelihood Of Confusion A..
AQ
04/27GILEAD SCIENCES : to support Indian COVID-19 crisis with donation of remdesivir
AQ
04/26GILEAD SCIENCES : Announces Steps to Expand Availability of Remdesivir in India
BU
04/21GILEAD SCIENCES : Statement on New England Journal of Medicine Publication of Po..
PU
04/21ELI LILLY AND : Japan health ministry panel OKs 3rd COVID-19 treatment drug
AQ
04/20Protara Therapeutics Announces Appointment of Martin Sebastian Olivo, M.D. as..
AQ
04/19Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of D..
AQ
04/15GILEAD SCIENCES : to Release First Quarter 2021 Financial Results on Thursday, A..
BU
04/14GILEAD SCIENCES : U.S. FDA Grants Accelerated Approval to Trodelvy for the Treat..
AQ
04/13GILEAD SCIENCES : U.S. FDA Grants Accelerated Approval to Trodelvy® for the Trea..
BU
04/12GILEAD SCIENCES : Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study i..
PU
04/09GILEAD SCIENCES : Announces Additional Updates to The Advancing ACCESS® Patient ..
PU
04/08GILEAD SCIENCES : Announces Updates to The Advancing ACCESS® Patient Assistance/..
PU
04/08GILEAD SCIENCES : FDA Approves Trodelvy, the First Treatment for Metastatic Trip..
AQ
04/07GILEAD SCIENCES : FDA Approves Trodelvy®, the First Treatment for Metastatic Tri..
BU
04/01GILEAD SCIENCES : Kite Submits Supplemental Biologics License Application to U.S..
BU
03/31GILEAD SCIENCES : Comments on the Passing of John C. Martin, PhD
BU
03/29GILEAD SCIENCES : Appoints Flavius Martin, MD as Executive Vice President, Resea..
AQ
03/26GILEAD SCIENCES : European Medicines Agency Validates Marketing Authorization Ap..
AQ
03/26GILEAD SCIENCES : Appoints Flavius Martin, MD as Executive Vice President, Resea..
BU
03/25GILEAD SCIENCES : European Medicines Agency Validates Marketing Authorization Ap..
BU
03/19GILEAD SCIENCES : and Novo Nordisk expand NASH clinical collaboration
AQ
03/18GILEAD SCIENCES : and Merck to collaborate on long-acting HIV treatments
AQ
1  2  3  4  5  6  7  8  9  10Next
Official Publications
06/15Report 
06/10Report 
05/12Report 
05/12SEC Filing 8K 
05/06SEC Filing 10Q-1 
05/06Report 
Upcoming event on GILEAD SCIENCES, INC.